Joshua M. Lang

8.5k total citations · 1 hit paper
137 papers, 2.6k citations indexed

About

Joshua M. Lang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Joshua M. Lang has authored 137 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Pulmonary and Respiratory Medicine, 63 papers in Oncology and 38 papers in Cancer Research. Recurrent topics in Joshua M. Lang's work include Prostate Cancer Treatment and Research (45 papers), Cancer Genomics and Diagnostics (28 papers) and Cancer Cells and Metastasis (24 papers). Joshua M. Lang is often cited by papers focused on Prostate Cancer Treatment and Research (45 papers), Cancer Genomics and Diagnostics (28 papers) and Cancer Cells and Metastasis (24 papers). Joshua M. Lang collaborates with scholars based in United States, Canada and China. Joshua M. Lang's co-authors include David J. Beebe, Douglas G. McNeel, Timothy Krueger, Glenn Liu, Marı́a Virumbrales-Muñoz, José M. Ayuso, Scott M. Berry, Jamie M. Sperger, Benjamin P. Casavant and Jens C. Eickhoff and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Joshua M. Lang

123 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

2020 223 citations Jonathan E. Rosenberg, Srikala S. Sridhar et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Joshua M. Lang

Since Specialization

Citations

This map shows the geographic impact of Joshua M. Lang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua M. Lang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua M. Lang more than expected).

Fields of papers citing papers by Joshua M. Lang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua M. Lang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua M. Lang. The network helps show where Joshua M. Lang may publish in the future.

Co-authorship network of co-authors of Joshua M. Lang

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua M. Lang. A scholar is included among the top collaborators of Joshua M. Lang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua M. Lang. Joshua M. Lang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library 2025 ·Communications Biology ·Gihan S. Gunaratne, (unknown), (unknown), (unknown), (unknown), (unknown), Jason C. Mixdorf, Eduardo Aluicio‐Sarduy, Jonathan W. Engle, Eszter Boros, (unknown), Joshua M. Lang, Shuang G. Zhao, Reinier Hernandez, David Kosoff, Aaron M. LeBeau	0
2	Impacts of dietary arginine supplementation on performance, nutrient digestion and expression of proteins related to milk fatty acid and casein synthesis in early lactating dairy cows 2025 ·Animal nutrition ·Jing Zhang, Joshua M. Lang, (unknown), Yapeng Liu, Wenjie Huo, C.X. Pei, Qiang Liu	2
3	Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein 2024 ·Cancer Research Communications ·(unknown), (unknown), Gihan S. Gunaratne, (unknown), (unknown), (unknown), (unknown), Erika Héninger, (unknown), (unknown), Zachary T. Rosenkrans, Reinier Hernandez, Shuang G. Zhao, Joshua M. Lang, (unknown), David Kosoff, Aaron M. LeBeau	9
4	1648P Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI) 2024 ·Annals of Oncology ·Joshua M. Lang, (unknown), Susan F. Slovin, Jamie M. Sperger, Jennifer L. Schehr, (unknown), Alexandre Marcelo Hintz, Hamid Emamekhoo, Dana E. Rathkopf, Wassim Abida, K. Autio, (unknown), A. Mitchell, (unknown), Shuang G. Zhao, Jens C. Eickhoff, Scott M. Dehm, (unknown), Christos E. Kyriakopoulos	1
5	A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer. 2024 ·Journal of Clinical Oncology ·Evan Y. Yu, Luke T. Nordquist, Salim Yazji, Yisrael Katz, (unknown), (unknown), Mohamad A. Salkeni, Hamid Emamekhoo, Elisabeth I. Heath, Ivan de Kouchkovsky, Joshua M. Lang, Peter S. Nelson, James B. Breitmeyer, Lawrence Fong, Johann S. de Bono	0
6	Abstract 3696: Liquid biopsy biomarker analysis during treatment with 177Lu-PSMA-617 in castrate resistant prostate cancer 2024 ·Cancer Research ·Jamie M. Sperger, Marina N. Sharifi, (unknown), V. Carreño, Alex H. Chang, Shannon R. Reese, (unknown), Amy K. Taylor, (unknown), John M. Floberg, Shuang G. Zhao, Joshua M. Lang	0
7	A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer. 2024 ·Journal of Clinical Oncology ·Evan Y. Yu, Salim Yazji, Yisrael Katz, (unknown), Luke T. Nordquist, (unknown), Mohamad A. Salkeni, Joshua M. Lang, Peter S. Nelson, James B. Breitmeyer, Lawrence Fong, Johann S. de Bono	3
8	P-126 TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer 2023 ·Annals of Oncology ·Ana Oaknin, Funda Meric‐Bernstam, Joshua M. Lang, Kristen K. Ciombor, Isabelle Ray‐Coquard, Amit M. Oza, Kan Yonemori, Rui‐Hua Xu, (unknown), (unknown), (unknown), (unknown), Yelena Y. Janjigian	2
9	Association of emergent neuroendocrine prostate cancer detected by liquid biopsies with survival and treatment resistance. 2023 ·Journal of Clinical Oncology ·Amy K. Taylor, Jamie M. Sperger, Marina N. Sharifi, Yue Shi, (unknown), Jennifer L. Schehr, Hamid Emamekhoo, Christos E. Kyriakopoulos, Andrew J. Armstrong, Xiao X. Wei, Mary‐Ellen Taplin, Rana R. McKay, Shuang G. Zhao, Joshua M. Lang	1
10	Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer 2022 ·Clinical Cancer Research ·(unknown), Nicholas R. Rydzewski, Meng Zhang, Arian Lundberg, (unknown), Kyle T. Helzer, Joshua M. Lang, Rahul Aggarwal, Eric J. Small, David A. Quigley, Martin Sjöström, Shuang G. Zhao	9
11	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance 2021 ·Clinical Cancer Research ·Rana R. McKay, Lucia Kwak, Jett Crowdis, Jamie M. Sperger, Shuang G. Zhao, Wanling Xie, Lillian Werner, Rosina T. Lis, Zhenwei Zhang, Xiao X. Wei, Joshua M. Lang, Eliezer M. Van Allen, Rupal S. Bhatt, Evan Y. Yu, Peter S. Nelson, Glenn J. Bubley, Bruce Montgomery, Mary‐Ellen Taplin	21
12	A Unique Approach to Quality Improvement Within the Stroke System of Care Utilizing Developmental Evaluation 2020 ·Health Promotion Practice ·(unknown), (unknown), Joshua M. Lang, (unknown), (unknown)	1
13	EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma breakdown → 2020 ·Journal of Clinical Oncology ·Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, David C. Smith, Dean Ruether, Thomas W. Flaig, Joaquina Baranda, Joshua M. Lang, Elizabeth R. Plimack, Randeep Sangha, Elisabeth I. Heath, (unknown), David I. Quinn, Sandy Srinivas, Matthew I. Milowsky, Chunzhang Wu, Elaina M. Gartner, Peiying Zuo, Amal Melhem‐Bertrandt, Daniel P. Petrylak	223
14	MA01.03 Interim Safety Analysis of the Phase IB Trial of SBRT to All Sites of Oligometastatic NSCLC Combined with Durvalumab and Tremelimumab 2019 ·Journal of Thoracic Oncology ·Ticiana Leal, Joshua M. Lang, Zachary S. Morris, Jens C. Eickhoff, Anne M. Traynor, Toby C. Campbell, (unknown), M. Bassetti	1
15	Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration 2018 ·Cell Reports ·Yvona Ward, Ross Lake, Farhoud Faraji, Jamie M. Sperger, Philip Martin, (unknown), (unknown), (unknown), David J. Niles, Heather Tillman, JuanJuan Yin, Kent W. Hunter, Adam G. Sowalsky, Joshua M. Lang, Kathleen Kelly	117
16	Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation 2016 ·Clinical Cancer Research ·Jamie M. Sperger, (unknown), Allison W. Welsh, Benjamin P. Casavant, (unknown), (unknown), Erika Héninger, (unknown), (unknown), (unknown), David J. Guckenberger, Lakeesha Carmichael, Scott M. Dehm, Philip J. Stephens, David J. Beebe, Scott M. Berry, Joshua M. Lang	50
17	High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1 2016 ·PLoS ONE ·Jennifer L. Schehr, (unknown), Jay W. Warrick, David J. Guckenberger, (unknown), Jamie M. Sperger, Erika Héninger, Anwaar Saeed, Ticiana Leal, (unknown), Anne M. Traynor, Toby C. Campbell, Scott M. Berry, David J. Beebe, Joshua M. Lang	55
18	Serum albumin and short-term risk for mortality and cardiovascular disease among HIV-infected veterans 2013 ·AIDS ·Joshua M. Lang, Rebecca Scherzer, (unknown), Phyllis C. Tien, Carl Grünfeld, Michael G. Shlipak	20
19	Expression and Immunotherapeutic Targeting of the SSX Family of Cancer–Testis Antigens in Prostate Cancer 2011 ·Cancer Research ·Heath A. Smith, (unknown), Joshua M. Lang, Douglas G. McNeel	44
20	Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma 2011 ·Cancer Immunology Immunotherapy ·Joshua M. Lang, (unknown), Marianne Wallace, Mary Jane Staab, Dorothea Horvath, George Wilding, Glenn Liu, Jens C. Eickhoff, Douglas G. McNeel, Miroslav Malkovský	114

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact